Carina Biotech
Blood & Organ Banks · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Catherine Helen Spence Building 5 Unisa ...Phone Number
+61 418160425Website
www.carinabiotech.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
2
3
1
About Carina Biotech
Carina Biotech is dedicated to combating cancer through innovative CAR-T technologies, specifically targeting solid tumors such as advanced colorectal cancer. The company empowers patients by developing next-generation CAR-T therapies and has a proprietary multifunctional chemokine receptor platform. With a focus on advanced manufacturing processes, Carina Biotech is at the forefront of CAR-T therapy advancements. Their intended clients include patients suffering from cancer and healthcare professionals seeking cutting-edge treatment options.Explore more
Carina Biotech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Carina Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Carina Biotech
Earning: See what the market has to say on Carina Biotech recently announced quarterly report
Check if Carina Biotech has recently received funding, and reach out quickly before it becomes old news!
Click to see if Carina Biotech had a recent Job posting/layoffs
Carina Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Carina Biotech is spiking on competitors!
Funding: Get notified immidiatlly once Carina Biotech has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Carina Biotech launches new products
Recommended Actions
Find VP level buyers at Carina Biotech
Find 3 more new buyers
Compare Similar Companies to Carina Biotech
Compare insights from companies similar to Carina Biotech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Carina Biotech is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Carina Biotech is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Carina Biotech.
Carina Biotech Tech Stack
A closer look at the technologies used by Carina Biotech
See more technologies
Carina Biotech News & Media
Carina Biotech to Participate in Three Upcoming Conferences
ADELAIDE, Australia, May 24, 2023 (GLOBE NEWSWIRE) -- Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced that the management team will participate in the three upcoming conferences as follows:Carina Biotech to Present Details of Planned Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy Candidate CNA3103 for Metastatic Colorectal Cancer at 2023 ASCO Annual Meeting
ADELAIDE, Australia, May 01, 2023 (GLOBE NEWSWIRE) -- Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced a poster presentation showcasing its planned Phase 1/2a clinical trial of its LGR5-targeted CAR-T cell therapy candidate CNA3103 in patients with metastatic colorectal cancer (mCRC) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting that will take place in Chicago, Illinois on June 2-6.Carina Biotech Receives FDA “Safe to Proceed” Letter for IND Application for Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy Candidate for Treatment of Advanced Colorectal Cancer
ADELAIDE, Australia , Jan. 23, 2023 (GLOBE NEWSWIRE) -- Carina Biotech Pty Ltd (“Carina,” “the Company”), a cell therapy immuno-oncology company developing CAR-T and other adoptive cell therapies for the treatment of solid cancers, announced today that it has received the “safe to proceed” letter from the U.S. FDA for its Investigational New Drug (NDA) application to conduct a first-in-human Phase 1/2a clinical trial of CNA3103, its LGR5-targeted chimeric antigen receptor T cell (CAR-T) therapy
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Carina Biotech
Sign Up For FreeTo access detailed company insights
Carina Biotech is dedicated to combating cancer through innovative CAR-T technologies, specifically targeting solid tumors such as advanced colorectal cancer. The company empowers patients by developing next-generation CAR-T therapies and has a proprietary multifunctional chemokine receptor platform. With a focus on advanced manufacturing processes... Read More
